Immune-mediated pathology as a consequence of impaired immune reactions Research Program
Immune-mediated pathology as a consequence of impaired immune reactions
Immune-mediated pathology as a consequence of impaired immune reactions
Immune-mediated pathology as a consequence of impaired immune reactions

The goal of the CRC 1160

The Collaborative Research Center (CRC) 1160. “Immune-mediated pathology as a consequence of impaired immune reactions (IMPATH)” is a research consortium of clinical and basic immunologists exploring the basis of diseases mediated by the immune system.

The CRC sets out to challenge the traditional idea that an “overreaction” or “deviation“ of normal immune responses is pivotal to immune mediated pathology and that, consequently, immunosuppression is the appropriate therapeutic strategy for such disorders. Instead, the conceptual basis of the CRC is the idea that impaired immune reactions constitute a major prerequisite for immunopathology. This is what we call the “IMPATH paradox”. This paradox implies that immune reconstitution and/or immune stimulation rather than immunosuppression represent appropriate therapeutic principles for these forms of immunopathology.

Research Program
More Seminars More Workshops

Publications

Moeed A, Thilmany N, Beck F, Puthussery BK, Ortmann N, Haimovici A, Badr MT, Haghighi EB, Boerries M, Öllinger R, Rad R, Kirschnek S, Gentle IE, Donakonda S, Petric PP, Hummel JF, Pfaffendorf E, Zanetta P, Schell C, Schwemmle M, Weber A, Häcker G. 2024. The Caspase-Activated DNase drives inflammation and contributes to defense against viral infection. Cell Death Differ. 2024 Jun 7. doi: 10.1038/s41418-024-01320-7.

Conradt G, Hausser I, Nyström A. 2024. Epidermal or Dermal Collagen VII Is Sufficient for Skin Integrity: Insights to Anchoring Fibril Homeostasis. J Invest Dermatol. 2024 Jun;144(6):1301-1310.e7. doi: 10.1016/j.jid.2023.11.003.

Kessler S, Burke B, Andrieux G, Schinköthe J, Hamberger L, Kacza J, Zhan S, Reasoner C, Dutt TS, Kaukab Osman M, Henao-Tamayo M, Staniek J, Villena Ossa JF, Frank DT, Ma W, Ulrich R, Cathomen T, Boerries M, Rizzi M, Beer M, Schwemmle M, Reuther P, Schountz T, Ciminski K. 2024. Deciphering bat influenza H18N11 infection dynamics in male Jamaican fruit bats on a single-cell level. Nat Commun. 2024 May 27;15(1):4500. doi: 10.1038/s41467-024-48934-6.

Zmajkovicova K, Pawar S, Sharapova SO, Geier CB, Wiest I, Nguyen C, Monticelli H, Maier-Munsa S, Chen K, Sleasman JW, Aleshkevich S, Polyakova E, Sakovich I, Warnatz KGrimbacher B, Proietti M, Sondheimer N, Ujhazi B, Gordon S, Ellison M, Yilmaz M, Walter JE, Badarau A, Taveras AG, Neff JL, Bledsoe JR, Tarrant TK. 2024. A Novel Transmembrane CXCR4 Variant That Expands the WHIM Genotype-Phenotype Paradigm. Blood Adv. 2024 May 20:bloodadvances.2023011875. doi: 10.1182/bloodadvances.2023011875.

Vinnakota JM, Biavasco F, Schwabenland M, Chhatbar C, Adams RC, Erny D, Duquesne S, El Khawanky N, Schmidt D, Fetsch V, Zähringer A, Salié H, Athanassopoulos D, Braun LM, Javorniczky NR, Ho JNHG, Kierdorf K, Marks R, Wäsch R, Simonetta F, Andrieux G, Pfeifer D, Monaco G, Capitini C, Fry TJ, Blank T, Blazar BR, Wagner E, Theobald M, Sommer C, Stelljes M, Reicherts C, Jeibmann A, Schittenhelm J, Monoranu CM, Rosenwald A, Kortüm M, Rasche L, Einsele H, Meyer PT, Brumberg J, Völkl S, Mackensen A, Coras R, von Bergwelt-Baildon M, Albert NL, Bartos LM, Brendel M, Holzgreve A, Mack M, Boerries M, Mackall CL, Duyster J, Henneke P, Priller J, Köhler N, Strübing F, Bengsch B, Ruella M, Subklewe M, von Baumgarten L, Gill S, Prinz M, Zeiser R. 2024. Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome. Nat Cancer. May 13. doi: 10.1038/s43018-024-00764-7.

More Publications